ADCT Stock Forecast 2025-2026
Distance to ADCT Price Targets
ADCT Price Momentum
10 Quality Stocks Worth Considering Now
Researching ADC Therapeutics (ADCT) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ADCT and similar high-potential opportunities.
Latest ADCT Stock Price Targets & Analyst Predictions
Based on our analysis of 12 Wall Street analysts, ADCT has a bullish consensus with a median price target of $8.00 (ranging from $7.00 to $10.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $1.36, the median forecast implies a 488.2% upside. This outlook is supported by 6 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Michael Schmidt at Guggenheim, projecting a 635.3% upside. Conversely, the most conservative target is provided by Michael Schmidt at Guggenheim, suggesting a 414.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ADCT Analyst Ratings
ADCT Price Target Range
Latest ADCT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ADCT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 31, 2025 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $8.00 |
| Mar 31, 2025 | Guggenheim | Michael Schmidt | Buy | Maintains | $7.00 |
| Mar 7, 2025 | Cantor Fitzgerald | Eric Schmidt | Overweight | Reiterates | $0.00 |
| Feb 24, 2025 | Stephens & Co. | Sudan Loganathan | Overweight | Maintains | $8.00 |
| Jan 6, 2025 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $8.00 |
| Dec 12, 2024 | Guggenheim | Michael Schmidt | Buy | Reiterates | $10.00 |
| Dec 11, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $0.00 |
| Nov 8, 2024 | Stephens & Co. | Sudan Loganathan | Overweight | Initiates | $6.00 |
| Aug 8, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $8.00 |
| Aug 7, 2024 | RBC Capital | Gregory Renza | Outperform | Reiterates | $8.00 |
| May 30, 2024 | Cantor Fitzgerald | Eric Schmidt | Overweight | Initiates | $0.00 |
| May 7, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $8.00 |
| Apr 15, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $9.00 |
| Apr 5, 2024 | Guggenheim | Michael Schmidt | Buy | Reiterates | $0.00 |
| Mar 28, 2024 | Guggenheim | Michael Schmidt | Buy | Initiates | $11.00 |
| Mar 14, 2024 | RBC Capital | Gregory Renza | Outperform | Reiterates | $8.00 |
| Mar 6, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $9.00 |
| Feb 26, 2024 | RBC Capital | Gregory Renza | Outperform | Maintains | $8.00 |
| Feb 20, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $9.00 |
| Nov 20, 2023 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $3.00 |
ADC Therapeutics S.A. (ADCT) Competitors
The following stocks are similar to ADC Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ADC Therapeutics S.A. (ADCT) Financial Data
ADC Therapeutics S.A. has a market capitalization of $127.94M with a P/E ratio of 0.0x. The company generates $70.84M in trailing twelve-month revenue with a -222.8% profit margin.
Revenue growth is +0.7% quarter-over-quarter, while maintaining an operating margin of -191.8% and return on equity of +77.9%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
ADC Therapeutics S.A. (ADCT) Business Model
About ADC Therapeutics S.A.
Develops antibody-drug conjugates for cancer treatment.
ADC Therapeutics generates revenue by developing and commercializing innovative antibody-drug conjugates (ADCs) that are designed to treat various types of cancers. The company aims to meet significant unmet medical needs by using targeted drug delivery systems that combine monoclonal antibodies with cytotoxic drugs, thus enhancing treatment efficacy while reducing side effects.
Headquartered in Switzerland, ADC Therapeutics is actively involved in clinical trials for its therapeutics targeting hematological cancers and solid tumors, including non-Hodgkin lymphoma. The company partners with research entities and employs advanced technology, positioning itself as a key player in the biopharmaceutical sector and contributing to advancements in oncology medicine.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
263
CEO
Dr. Ameet Mallik M.B.A., M.S.
Country
Switzerland
IPO Year
2020
Website
www.adctherapeutics.comADC Therapeutics S.A. (ADCT) Latest News & Analysis
Latest News
ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
23 days agoADC Therapeutics SA (NYSE: ADCT) CEO Ameet Mallik will present a company overview at the Needham Virtual Healthcare Conference on April 8, 2025, at 8:00 a.m. ET. A webcast will be available online.
Ameet Mallik's presentation at the healthcare conference may influence investor sentiment and stock performance for ADC Therapeutics, providing insights into the company's strategy and prospects.
ADC Therapeutics SA granted options to purchase 128,600 common shares to two new employees as an inducement for their employment on April 1, 2025.
The grant of stock options to new employees indicates ADC Therapeutics' commitment to attracting talent, which can enhance innovation and drive potential growth, impacting long-term shareholder value.
ADC Therapeutics (NYSE: ADCT) will hold its Q4 2024 earnings conference call on March 27, 2025, at 8:30 AM ET, featuring key company executives and analysts from various firms.
ADC Therapeutics' earnings call provides insights into financial performance and strategic direction, influencing stock valuation and investor sentiment. Key executives' commentary can signal future growth or risks.
ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update
28 days agoADC Therapeutics reported a 94% overall response rate and 72% complete response rate in the LOTIS-7 trial of ZYNLONTA. They have $250.9M cash, funding operations into H2 2026.
The strong clinical trial results for ZYNLONTA® suggest significant potential for market growth, while sufficient cash reserves ensure operational stability, impacting investor confidence positively.
ADC Therapeutics SA reported a quarterly loss of $0.29 per share, better than the Zacks Consensus Estimate of $0.35, and an improvement from a loss of $1.03 per share a year prior.
ADC Therapeutics' smaller-than-expected quarterly loss signals improved financial performance, potentially boosting investor confidence and impacting stock price positively.
ADC Therapeutics (NYSE: ADCT) will present preclinical data on Claudin-6, PSMA, and ASCT2-targeted ADCs at the AACR Annual Meeting 2025 in Chicago, April 25-30.
Positive preclinical data on ADCs could indicate potential breakthroughs in cancer treatment, influencing stock performance and investor sentiment for ADC Therapeutics.
Frequently Asked Questions About ADCT Stock
What is ADC Therapeutics S.A.'s (ADCT) stock forecast for 2025?
Based on our analysis of 12 Wall Street analysts, ADC Therapeutics S.A. (ADCT) has a median price target of $8.00. The highest price target is $10.00 and the lowest is $7.00.
Is ADCT stock a good investment in 2025?
According to current analyst ratings, ADCT has 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.36. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ADCT stock?
Wall Street analysts predict ADCT stock could reach $8.00 in the next 12 months. This represents a 488.2% increase from the current price of $1.36. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is ADC Therapeutics S.A.'s business model?
ADC Therapeutics generates revenue by developing and commercializing innovative antibody-drug conjugates (ADCs) that are designed to treat various types of cancers. The company aims to meet significant unmet medical needs by using targeted drug delivery systems that combine monoclonal antibodies with cytotoxic drugs, thus enhancing treatment efficacy while reducing side effects.
What is the highest forecasted price for ADCT ADC Therapeutics S.A.?
The highest price target for ADCT is $10.00 from Michael Schmidt at Guggenheim, which represents a 635.3% increase from the current price of $1.36.
What is the lowest forecasted price for ADCT ADC Therapeutics S.A.?
The lowest price target for ADCT is $7.00 from Michael Schmidt at Guggenheim, which represents a 414.7% increase from the current price of $1.36.
What is the overall ADCT consensus from analysts for ADC Therapeutics S.A.?
The overall analyst consensus for ADCT is bullish. Out of 12 Wall Street analysts, 6 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $8.00.
How accurate are ADCT stock price projections?
Stock price projections, including those for ADC Therapeutics S.A., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.